U.S. patent application number 17/180157 was filed with the patent office on 2021-06-10 for antimicrobial phase-separable glass/polymer composite articles and methods for making the same.
The applicant listed for this patent is CORNING INCORPORATED. Invention is credited to Dayue Jiang, Kaitlyn Mary Matias, Kevin Andrew Vasilakos, Jianguo Wang, Jie Wang.
Application Number | 20210169085 17/180157 |
Document ID | / |
Family ID | 1000005406090 |
Filed Date | 2021-06-10 |
United States Patent
Application |
20210169085 |
Kind Code |
A1 |
Jiang; Dayue ; et
al. |
June 10, 2021 |
ANTIMICROBIAL PHASE-SEPARABLE GLASS/POLYMER COMPOSITE ARTICLES AND
METHODS FOR MAKING THE SAME
Abstract
A method of making an antimicrobial composite article, including
the steps: providing a matrix comprising a polymeric material;
providing a plurality of second phase particles comprising an
antimicrobial agent; melting the matrix to form a matrix melt;
distributing the plurality of second phase particles in the matrix
melt at a second phase volume fraction to form a composite melt;
forming a composite article from the composite melt; and treating
the composite article to form an antimicrobial composite article
having an exterior surface comprising an exposed portion of the
matrix and the plurality of second phase particles. The
distributing step can employ an extrusion process. The forming a
composite article step can employ an injection molding process. The
treating step can employ abrading and plasma-treating the article
to define the exterior surface.
Inventors: |
Jiang; Dayue; (Painted Post,
NY) ; Matias; Kaitlyn Mary; (Corning, NY) ;
Vasilakos; Kevin Andrew; (Painted Post, NY) ; Wang;
Jianguo; (Horseheads, NY) ; Wang; Jie;
(Weston, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CORNING INCORPORATED |
CORNING |
NY |
US |
|
|
Family ID: |
1000005406090 |
Appl. No.: |
17/180157 |
Filed: |
February 19, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15769943 |
Apr 20, 2018 |
10959434 |
|
|
PCT/US16/57804 |
Oct 20, 2016 |
|
|
|
17180157 |
|
|
|
|
62244368 |
Oct 21, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C09D 5/025 20130101;
C08K 13/02 20130101; C09K 9/00 20130101; C03C 2204/02 20130101;
A41D 31/30 20190201; B01D 2325/48 20130101; C03C 4/0035 20130101;
C11D 3/485 20130101; C03C 2214/04 20130101; C09D 7/66 20180101;
C08K 3/015 20180101; C08K 3/22 20130101; C08K 2003/2248 20130101;
B01D 2239/0442 20130101; C09D 5/14 20130101; C03C 2214/16 20130101;
C11D 3/48 20130101; C03C 14/006 20130101; A01N 59/20 20130101; C08K
3/40 20130101; C03C 14/004 20130101; C09D 7/61 20180101 |
International
Class: |
A01N 59/20 20060101
A01N059/20; C08K 3/40 20060101 C08K003/40; C11D 3/48 20060101
C11D003/48; C08K 13/02 20060101 C08K013/02; C09K 9/00 20060101
C09K009/00; C03C 14/00 20060101 C03C014/00; C03C 4/00 20060101
C03C004/00; A41D 31/30 20190101 A41D031/30; C09D 7/40 20180101
C09D007/40; C09D 5/02 20060101 C09D005/02; C09D 5/14 20060101
C09D005/14; C08K 3/22 20060101 C08K003/22; C09D 7/61 20180101
C09D007/61 |
Claims
1. A method of making an antimicrobial composite article,
comprising the steps: melting a matrix comprising a polymeric
material to form a matrix melt; distributing a plurality of second
phase particles comprising an antimicrobial agent in the matrix
melt at a second phase volume fraction to form a composite melt;
forming a composite article from the composite melt; and treating
the composite article to form an antimicrobial composite article
comprising an exterior surface comprising an exposed portion of the
matrix and the plurality of second phase particles.
2. The method of claim 1, wherein the polymeric material of the
matrix is characterized by substantial hydrophilicity, as measured
by a contact angle between water and the polymeric material of less
than 90.degree..
3. The method of claim 1, wherein the treating step comprises
abrading the composite article to form an antimicrobial composite
article comprising an exterior surface comprising an exposed
portion of the matrix and the plurality of second phase
particles.
4. The method of claim 1, wherein the polymeric material of the
matrix is characterized by substantial hydrophobicity, as measured
by a contact angle between water and the polymeric material of
greater than 90.degree., and further wherein the exposed portion of
the matrix is characterized by substantial hydrophilicity.
5. The method of claim 4, wherein the treating step comprises
abrading and plasma-treating the composite article to form the
antimicrobial composite article having an exterior surface
comprising an exposed portion of the matrix and the plurality of
second phase particles.
6. The method of claim 5, wherein the abrading is performed before
the plasma-treating during the treating step.
7. The method of claim 5, wherein the plasma-treating is performed
before the abrading during the treating step.
8. The method of claim 1, wherein the second phase particles
comprise a phase-separated glass, and the antimicrobial agent
comprises a copper-containing antimicrobial agent.
9. The method of claim 8, wherein the phase-separated glass
comprises SiO.sub.2 and at least one of B.sub.2O.sub.3,
P.sub.2O.sub.5, or R.sub.2O, and wherein the copper-containing
antimicrobial agent is cuprite comprising a plurality of Cu.sup.1+
ions.
10. The method of claim 1, wherein the polymeric material is
selected from the group consisting of a polypropylene, a
polyolefin, and a polysulfone.
11. The method of claim 1, wherein the melting and distributing
steps comprise an extrusion process, and the forming a composite
article step comprises an injection molding process.
12. The method of claim 1, wherein the exterior surface of the
antimicrobial composite article exhibits at least a log 2 reduction
in a concentration of at least one of Staphylococcus aureus,
Enterobacter aerogenes, and Pseudomonas aeruginosa bacteria under a
Modified EPA Copper Test Protocol.
13. The method of claim 1, wherein the exterior surface of the
antimicrobial composite article exhibits at least a log 3 reduction
in a concentration of at least one of Staphylococcus aureus,
Enterobacter aerogenes, and Pseudomonas aeruginosa bacteria under a
Modified EPA Copper Test Protocol.
14. A method of making an antimicrobial composite article,
comprising the steps: melting a matrix comprising a polymeric
material to form a matrix melt; distributing a plurality of second
phase particles comprising a phase-separated glass comprising a
copper-containing antimicrobial agent in the matrix melt at a
second phase volume fraction to form a composite melt; forming a
composite article from the composite melt; and treating the
composite article to form an antimicrobial composite article
comprising an exterior surface comprising an exposed portion of the
matrix and the plurality of second phase particles.
15. The method of claim 14, wherein the treating step comprises
abrading the composite article to form the antimicrobial composite
article having an exterior surface comprising an exposed portion of
the matrix and the plurality of second phase particles.
16. The method of claim 14, wherein the treating step comprises
plasma-treating the composite article to form the antimicrobial
composite article having an exterior surface comprising an exposed
portion of the matrix and the plurality of second phase
particles.
17. The method of claim 14, wherein the treating step comprises
abrading and plasma-treating the composite article to form the
antimicrobial composite article having an exterior surface
comprising an exposed portion of the matrix and the plurality of
second phase particles.
18. The method of claim 14, wherein the phase-separated glass
comprises SiO.sub.2 and at least one of B.sub.2O.sub.3,
P.sub.2O.sub.5, or R.sub.2O, and wherein the copper-containing
antimicrobial agent is cuprite comprising a plurality of Cu.sup.1+
ions.
19. The method of claim 14, wherein the polymeric material is
selected from the group consisting of a polypropylene, a
polyolefin, and a polysulfone.
20. A method of making an antimicrobial composite article,
comprising the steps: melting a matrix comprising a hydrophobic
polymeric material to form a matrix melt; extruding a plurality of
second phase particles comprising a copper-containing antimicrobial
agent in the matrix melt at a second phase volume fraction to form
a composite melt; injection molding a composite article from the
composite melt; and treating the composite article to form an
antimicrobial composite article comprising an exterior surface
comprising an exposed portion of the matrix and the plurality of
second phase particles, wherein the exposed portion of the
plurality of second phase particles is distributed within the
exposed portion of the matrix at a second phase area fraction
within 25% of the second phase volume fraction.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 15/769,943 filed on Apr. 20, 2018, which claims the
benefit of priority under 35 U.S.C. .sctn. 371 of International
Application No. PCT/US2016/057804, filed on Oct. 20, 2016, which
claims the benefit of priority under 35 U.S.C. .sctn. 119 of U.S.
Provisional Application Ser. No. 62/244,368 filed on Oct. 21, 2015,
the content of each of which is relied upon and incorporated herein
by reference in its entirety.
BACKGROUND
[0002] The present disclosure relates generally to antimicrobial
composite articles and methods for making them. More particularly,
the various embodiments described herein relate to glass/polymer
composite antimicrobial articles having copper-containing
antimicrobial agents and various methods for making them.
[0003] Consumer electronics articles, including touch-activated or
touch-interactive devices, such as screen surfaces (e.g., surfaces
of electronic devices having user-interactive capabilities that are
activated by touching specific portions of the surfaces), have
become increasingly more prevalent. As the extent to which the
touch screen-based interactions between a user and a device
increases, so too does the likelihood of the surface harboring
microorganisms (e.g., bacteria, fungi, viruses, and the like) that
can be transferred from user to user. Moreover, the housings which
incorporate the touch-activated or touch-interactive devices also
include surfaces that harbor such microorganisms that can be
transferred from user to user. The concern of microorganism
transfer is also a concern with many "high touch" surfaces
associated with various electronic equipment, furniture and
architectural articles, counter-tops, table-tops, control panels
and other articles used in medical, office and consumer settings in
which users, consumers or the like come into contact with these
surfaces.
[0004] To minimize the presence of microbes on various materials,
so-called "antimicrobial" properties have been imparted to a
variety of glasses; however, there is a need to provide entire
articles (including the housing and any glasses used as cover
glass) that also exhibit antimicrobial properties. Accordingly,
antimicrobial articles useful for certain applications should be
durable enough for the purpose for which they are used, while also
providing continuous antimicrobial properties that are passive or
do not require additional activation by a user or outside source
(e.g., UV light). In addition, antimicrobial glasses and articles
should provide controlled antimicrobial activity.
[0005] In some situations, polymer/glass composite articles
intended to exhibit antimicrobial properties demonstrate far less
antimicrobial efficacy. One problem associated with such articles
is ensuring that the antimicrobial agents are present at the
surfaces of these articles at a concentration sufficient to provide
the desired antimicrobial efficacy. Another problem is ensuring
that the microbes present on the surfaces of such article are in
residence for a sufficient duration to be killed or neutralized by
the antimicrobial agents within the composite articles.
[0006] Accordingly, there is a need for antimicrobial composites
articles possessing exterior surfaces that can be configured to
produce desired antimicrobial efficacy levels, along with processes
for making the same.
SUMMARY
[0007] A first aspect of the present disclosure pertains to an
antimicrobial composite article that includes: a matrix comprising
a polymeric material; and a plurality of second phase particles
comprising a phase-separable glass with a copper-containing
antimicrobial agent. The plurality of particles is distributed
within the matrix at a second phase volume fraction. Further, the
composite article defines an exterior surface comprising an exposed
portion of the matrix and the plurality of the second phase
particles.
[0008] The second phase particles of the antimicrobial composite
article in some aspects can include phase-separable glass that
includes at least one of B.sub.2O.sub.3, P.sub.2O.sub.5 and
R.sub.2O, and the antimicrobial agent is cuprite which includes a
plurality of Cu.sup.1+ ions. In certain aspects, the plurality of
second phase particles has a size distribution defined by a 325
standard US mesh size. Further, the phase-separable glass can
comprise between about 10 and 50 mol % cuprite.
[0009] The matrix of the antimicrobial composite article in some
aspects can include a polymeric material selected from the group
consisting of a polypropylene, a polyolefin and a polysulfone. In
certain aspects, the polymeric material can be characterized by
substantial hydrophobicity, while the exposed portion of the matrix
is characterized by substantial hydrophilicity. Other aspects of
the antimicrobial composite article employ a matrix with a
polymeric material characterized by substantial hydrophilicity
(e.g., within its bulk and on its exposed surfaces and portions).
In addition, the exposed portion of the matrix can comprise
functional groups derived from a plasma treatment of the
matrix.
[0010] In some implementations of the antimicrobial composite
article, the exterior surface of the article exhibits at least a
log 2 reduction in a concentration of at least one of
Staphylococcus aureus, Enterobacter aerogenes, and Pseudomonas
aeruginosa bacteria under modified United States Environmental
Protection Agency "Test Method for Efficacy of Copper Alloy
Surfaces as a Sanitizer" testing conditions, wherein the modified
conditions include substitution of the antimicrobial composite
article with the copper-containing surface prescribed in the Method
and use of copper metal article as the prescribed control sample in
the Method (collectively, the "Modified EPA Copper Test Protocol").
In certain aspects, the exterior surface can exhibit at least a log
3, log 4, or even a log 5, reduction of the same bacteria under the
same Modified EPA Copper Test Protocol test conditions.
[0011] A second aspect of the disclosure pertains to a method of
making an antimicrobial composite article, including the steps:
providing a matrix comprising a polymeric material; providing a
plurality of second phase particles comprising an antimicrobial
agent; melting the matrix to form a matrix melt; distributing the
plurality of second phase particles in the matrix melt at a second
phase volume fraction to form a composite melt; forming a composite
article from the composite melt; and treating the composite article
to form an antimicrobial composite article having an exterior
surface comprising an exposed portion of the matrix and the
plurality of second phase particles.
[0012] The treating step of the method of making the antimicrobial
composite article in some aspects can include abrading the
composite article to form an antimicrobial composite article having
an exterior surface comprising an exposed portion of the matrix and
the plurality of second phase particles. The abrading can be
conducted with hand sanding, grit blasting or other similar
grinding and/or polishing techniques. In other aspects of the
method, the treating step can include abrading and plasma-treating
the composite article to form an antimicrobial composite article
having an exterior surface comprising an exposed portion of the
matrix and the plurality of second phase particles. In these
implementations, the abrading can be performed before the
plasma-treating or vice versa. Further, the plasma-treating can
conducted with any of a variety of known processes that produce or
otherwise create functional groups in the exposed portion of the
matrix on the exterior surface of the article.
[0013] According to some aspects of the method, the melting and
distributing steps can include or otherwise employ an extrusion
process. Further, the forming a composite article step can include
or otherwise employ an injection molding process. As such, the
forming step can be employed to fashion the composite article in a
final product form or a near net shape form.
[0014] A third aspect of the disclosure pertains to a method of
making an antimicrobial composite article, including the steps:
providing a matrix comprising a hydrophobic polymeric material;
providing a plurality of second phase particles comprising a
copper-containing antimicrobial agent; melting the matrix to form a
matrix melt; extruding the plurality of second phase particles in
the matrix melt at a second phase volume fraction to form a
composite melt; injection molding a composite article from the
composite melt; and treating the composite article to form an
antimicrobial composite article having an exterior surface
comprising an exposed portion of the matrix and the plurality of
second phase particles. Further, the exposed portion of the
plurality of second phase particles is distributed within the
exposed portion of the matrix at a second phase area fraction
within 25% of the second phase volume fraction.
[0015] Additional features and advantages will be set forth in the
detailed description which follows, and in part will be readily
apparent to those skilled in the art from that description or
recognized by practicing the embodiments as described herein,
including the detailed description which follows, the claims, as
well as the appended drawings.
[0016] It is to be understood that both the foregoing general
description and the following detailed description are merely
exemplary, and are intended to provide an overview or framework to
understanding the nature and character of the claims. The
accompanying drawings are included to provide a further
understanding, and are incorporated in and constitute a part of
this specification. The drawings illustrate one or more
embodiment(s), and together with the description serve to explain
principles and operation of the various embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG. 1 is a schematic, perspective view of an antimicrobial
composite article according to an aspect of the disclosure.
[0018] FIG. TA is a plan view of an exterior surface of the
antimicrobial composite article depicted in FIG. 1 that comprises
an exposed portion of the matrix and second phase particles.
[0019] FIG. 1B is an energy dispersive spectroscopy (EDS) image of
phase-separable glass in an exterior surface of an antimicrobial
composite article according to an aspect of the disclosure that is
comparable to the antimicrobial composite article schematically
depicted in FIG. 1.
[0020] FIG. 2 are photographs of antimicrobial composite strip and
pellet articles having a polypropylene matrix and a plurality of
second phase particles comprising a phase-separable glass with a
copper-containing antimicrobial agent according to another aspect
of the disclosure.
[0021] FIG. 3 are photographs of antimicrobial composite articles
having a polypropylene matrix and a plurality of second phase
particles comprising a phase-separable glass with a
copper-containing antimicrobial agent that are configured in the
form of test coupons for assessing antimicrobial efficacy with the
Modified EPA Copper Test Protocol.
[0022] FIG. 4 are optical micrographs of an exterior surface of
antimicrobial composite articles having a polypropylene matrix and
a plurality of second phase particles comprising a phase-separable
glass with a copper-containing antimicrobial agent before and after
a hand-sanding abrasion step according to an aspect of the
disclosure.
[0023] FIG. 5 are optical micrographs of an exterior surface of the
antimicrobial composite articles depicted in FIG. 4, as contacted
with a bacteria-containing aqueous solution before and after a
plasma-treatment step according to an aspect of the disclosure.
[0024] FIG. 6 is a schematic flow chart of a method of making an
antimicrobial composite article according to a further aspect of
the disclosure.
[0025] FIG. 7A is a bar chart depicting the antimicrobial efficacy
of antimicrobial composite articles having a polypropylene matrix
and a plurality of second phase particles comprising a
phase-separable glass with a copper-containing antimicrobial agent,
and subjected to various surface treatment steps.
[0026] FIG. 7B is a bar chart depicting the antimicrobial efficacy
of antimicrobial composite articles having a polypropylene matrix
and a plurality of second phase particles comprising a
phase-separable glass with a copper-containing antimicrobial agent,
and subjected to various surface treatment steps.
[0027] FIGS. 8A & 8B are bar charts depicting the antimicrobial
efficacy of antimicrobial composite articles having a polysulfone
matrix and a plurality of second phase particles comprising a
phase-separable glass with a copper-containing antimicrobial agent,
and subjected to various surface treatment steps.
[0028] FIG. 9 is a bar chart depicting the antimicrobial efficacy
of antimicrobial composite articles having a polypropylene matrix
and a plurality of second phase particles comprising a
phase-separable glass with a copper-containing antimicrobial agent,
and subjected to various hospital grade cleaners.
[0029] FIGS. 10A & 10B are bar charts depicting the
antimicrobial efficacy of antimicrobial composite articles having a
polypropylene matrix and a plurality of second phase particles
comprising a phase-separable glass with a copper-containing
antimicrobial agent, and subjected to various environmental
conditions.
[0030] FIG. 11 is a bar chart depicts the antimicrobial efficacy of
antimicrobial composite articles having a polypropylene matrix and
a plurality of second phase particles comprising a phase-separable
glass with a copper-containing antimicrobial agent, with and
without a subsequent fluorosilane layer over the exterior surfaces
of the article.
DETAILED DESCRIPTION
[0031] Reference will now be made in detail to various
embodiment(s), examples of which are illustrated in the
accompanying drawings.
[0032] Aspects of the disclosure generally pertain to antimicrobial
composite articles that include secondary particles comprising
glass compositions with antimicrobial properties. The antimicrobial
properties of the glasses disclosed herein include antiviral and/or
antibacterial properties. As used herein the term "antimicrobial,"
means a material, or a surface of a material that will kill or
inhibit the growth of bacteria, viruses and/or fungi. The term as
used herein does not mean the material or the surface of the
material will kill or inhibit the growth of all species microbes
within such families, but that it will kill or inhibit the growth
or one or more species of microbes from such families.
[0033] As used herein the term "log reduction" means--log
(C.sub.a/C.sub.0), where Ca=the colony form unit (CFU) number of
the antimicrobial surface and C.sub.0=the colony form unit (CFU) of
the control surface that is not an antimicrobial surface. As an
example, a "3 log" reduction equals about 99.9% of the bacteria,
viruses and/or fungi killed. Similarly, a "5 log" reduction equals
about 99.999% of bacteria, viruses and/or fungi killed.
[0034] Referring to FIG. 1, an antimicrobial composite article 100
is provided in an exemplary, schematic form. The article 100
includes a matrix 10 that comprises a polymeric material. The
article 100 also includes a plurality of second phase particles 20.
The particles 20 comprise a phase-separable glass with a
copper-containing antimicrobial agent. Further, the plurality of
particles 20 is distributed within the matrix 10 at a second phase
volume fraction. As also depicted in FIG. 1, the composite article
100 defines an exterior surface 40 that includes an exposed portion
of the matrix 10 and the plurality of the second phase particles
20. The exposed portion of the exterior surface 40 is also depicted
in the plan view of FIG. 1A. In certain implementations, other
exterior surfaces 30 of the article 100 can also include such
exposed portions.
[0035] Referring again to FIG. 1, the exposed portion of the
exterior surface 40 can, at least in some aspects, contain a
certain percentage of second phase particles 20 that have been
bisected or are otherwise sectioned such that their interiors are
exposed. In certain implementations, the exposed portion of the
plurality of the second phase particles 20 can be distributed
within the exposed portion of the matrix 10 at a second phase area
fraction within .+-.25% of the second phase volume fraction. That
is, the exposed portion of the exterior surface possesses roughly
the same or similar percentage of second phase particles as the
bulk of the antimicrobial composite article 100.
[0036] As outlined earlier, the second phase particles 20 include a
phase-separable glass with a copper-containing antimicrobial agent.
The phase-separable glass employed in the particles 20 is described
in U.S. patent application Ser. No. 14/623,077, filed on Feb. 16,
2015, the salient portions of which related to phase-separable
glass are hereby incorporated by reference within this disclosure.
In one or more embodiments, the phase-separable glasses employed in
the second phase particles 20 include a Cu species. In one or more
alternative embodiments, the Cu species may include Cu.sup.1+,
Cu.sup.0, and/or Cu.sup.2+. The combined total of the Cu species
may be about 10 wt % or more. However, as will be discussed in more
detail below, the amount of Cu.sup.2+ is minimized or is reduced
such that the antimicrobial glass is substantially free of
Cu.sup.2+. The Cu.sup.1+ ions may be present on or in the surface
and/or the bulk of the antimicrobial glass. In some embodiments,
the Cu.sup.1+ ions are present in the glass network and/or the
glass matrix of the antimicrobial glass. Where the Cu.sup.1+ ions
are present in the glass network, the Cu.sup.1+ ions are atomically
bonded to the atoms in the glass network. Where the Cu.sup.1+ ions
are present in the glass matrix, the Cu.sup.1+ ions may be present
in the form of Cu.sup.1+ crystals that are dispersed in the glass
matrix. In some embodiments the Cu.sup.1+ crystals include cuprite
(Cu.sub.2O). In such embodiments, where Cu.sup.1+ crystals are
present, the material may be referred to as an antimicrobial glass
ceramic, which is intended to refer to a specific type of glass
with crystals that may or may not be subjected to a traditional
ceramming process by which one or more crystalline phases are
introduced and/or generated in the glass. Where the Cu.sup.1+ ions
are present in a non-crystalline form, the material may be referred
to as an antimicrobial glass. In some embodiments, both Cu.sup.1+
crystals and Cu.sup.1+ ions not associated with a crystal are
present in the antimicrobial glasses described herein.
[0037] In one or more aspects of the antimicrobial composite
article 100, the antimicrobial glass employed in the second phase
particles 20 may be formed from a composition that can include, in
mole percent, SiO.sub.2 in the range from about 40 to about 70,
Al.sub.2O.sub.3 in the range from about 0 to about 20, a
copper-containing oxide in the range from about 10 to about 30, CaO
in the range from about 0 to about 15, MgO in the range from about
0 to about 15, P.sub.2O.sub.5 in the range from about 0 to about
25, B.sub.2O.sub.3 in the range from about 0 to about 25, K.sub.2O
in the range from about 0 to about 20, ZnO in the range from about
0 to about 5, Na.sub.2O in the range from about 0 to about 20,
and/or Fe.sub.2O.sub.3 in the range from about 0 to about 5. In
such embodiments, the amount of the copper-containing oxide is
greater than the amount of Al.sub.2O.sub.3. In some embodiments,
the composition may include a content of R.sub.2O, where R may
include K, Na, Li, Rb, Cs and combinations thereof.
[0038] In the embodiments of the compositions described herein,
SiO.sub.2 serves as the primary glass-forming oxide. The amount of
SiO.sub.2 present in a composition should be enough to provide
glasses that exhibit the requisite chemical durability suitable for
its use or application within the antimicrobial composite article
100 (e.g., touch applications, article housing etc.). The upper
limit of SiO.sub.2 may be selected to control the melting
temperature of the compositions described herein. For example,
excess SiO.sub.2 could drive the melting temperature at 200 poise
to high temperatures at which defects such as fining bubbles may
appear or be generated during processing and in the resulting
glass. Furthermore, compared to most oxides, SiO.sub.2 decreases
the compressive stress created by an ion exchange process of the
resulting glass. In other words, glass formed from compositions
with excess SiO.sub.2 may not be ion-exchangeable to the same
degree as glass formed from compositions without excess SiO.sub.2.
Additionally or alternatively, SiO.sub.2 present in the
compositions according to one or more embodiments could increase
the plastic deformation prior break properties of the resulting
glass. An increased SiO.sub.2 content in the glass formed from the
compositions described herein may also increase the indentation
fracture threshold of the glass.
[0039] In one or more aspects of the antimicrobial composite
article 100, the composition of the glass employed in the second
phase particles 20 includes SiO.sub.2 in an amount, in mole
percent, in the range from about 40 to about 70, from about 40 to
about 69, from about 40 to about 68, from about 40 to about 67,
from about 40 to about 66, from about 40 to about 65, from about 40
to about 64, from about 40 to about 63, from about 40 to about 62,
from about 40 to about 61, from about 40 to about 60, from about 41
to about 70, from about 42 to about 70, from about 43 to about 70,
from about 44 to about 70, from about 45 to about 70, from about 46
to about 70, from about 47 to about 70, from about 48 to about 70,
from about 49 to about 70, from about 50 to about 70, from about 41
to about 69, from about 42 to about 68, from about 43 to about 67
from about 44 to about 66 from about 45 to about 65, from about 46
to about 64, from about 47 to about 63, from about 48 to about 62,
from about 49 to about 61, from about 50 to about 60 and all ranges
and sub-ranges therebetween.
[0040] In one or more aspects of the antimicrobial composite
article 100, the composition of the glass employed in the second
phase particles 20 includes Al.sub.2O.sub.3 an amount, in mole
percent, in the range from about 0 to about 20, from about 0 to
about 19, from about 0 to about 18, from about 0 to about 17, from
about 0 to about 16, from about 0 to about 15, from about 0 to
about 14, from about 0 to about 13, from about 0 to about 12, from
about 0 to about 11 from about 0 to about 10, from about 0 to about
9, from about 0 to about 8, from about 0 to about 7, from about 0
to about 6, from about 0 to about 5, from about 0 to about 4, from
about 0 to about 3, from about 0 to about 2, from about 0 to about
1, from about 0.1 to about 1, from about 0.2 to about 1, from about
0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1,
from about 0 to about 0.5, from about 0 to about 0.4, from about 0
to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1
and all ranges and sub-ranges therebetween. In some embodiments,
the composition is substantially free of Al.sub.2O.sub.3. As used
herein, the phrase "substantially free" with respect to the
components of the composition and/or resulting glass means that the
component is not actively or intentionally added to the
compositions during initial batching or subsequent post processing
(e.g., ion exchange process), but may be present as an impurity.
For example, a composition, a glass may be describe as being
substantially free of a component, when the component is present in
an amount of less than about 0.01 mol %.
[0041] The amount of Al.sub.2O.sub.3 may be adjusted to serve as a
glass-forming oxide and/or to control the viscosity of molten
compositions within the glass employed in the second phase
particles 20. Without being bound by theory, it is believed that
when the concentration of alkali oxide (R.sub.2O) in a composition
is equal to or greater than the concentration of Al.sub.2O.sub.3,
the aluminum ions are found in tetrahedral coordination with the
alkali ions acting as charge-balancers. This tetrahedral
coordination greatly enhances various post-processing (e.g., ion
exchange process) of glasses formed from such compositions.
Divalent cation oxides (RO) can also charge balance tetrahedral
aluminum to various extents. While elements such as calcium, zinc,
strontium, and barium behave equivalently to two alkali ions, the
high field strength of magnesium ions causes them to not fully
charge balance aluminum in tetrahedral coordination, resulting in
the formation of five- and six-fold coordinated aluminum.
Generally, Al.sub.2O.sub.3 can play an important role in
ion-exchangeable compositions and strengthened glasses since it
enables a strong network backbone (i.e., high strain point) while
allowing for the relatively fast diffusivity of alkali ions.
However, when the concentration of Al.sub.2O.sub.3 is too high, the
composition may exhibit lower liquidus viscosity and, thus,
Al.sub.2O.sub.3 concentration may be controlled within a reasonable
range. Moreover, as will be discussed in more detail below, excess
Al.sub.2O.sub.3 has been found to promote the formation of Cu.sup.2
ions, instead of the desired Cu.sup.1+ ions.
[0042] In one or more aspects of the antimicrobial composite
article 100, the composition of the glass employed in the second
phase particles 20 includes a copper-containing oxide in an amount,
in mole percent, in the range from about 10 to about 50, from about
10 to about 49, from about 10 to about 48, from about 10 to about
47, from about 10 to about 46, from about 10 to about 45, from
about 10 to about 44, from about 10 to about 43, from about 10 to
about 42, from about 10 to about 41, from about 10 to about 40,
from about 10 to about 39, from about 10 to about 38, from about 10
to about 37, from about 10 to about 36, from about 10 to about 35,
from about 10 to about 34, from about 10 to about 33, from about 10
to about 32, from about 10 to about 31, from about 10 to about 30,
from about 10 to about 29, from about 10 to about 28, from about 10
to about 27, from about 10 to about 26, from about 10 to about 25,
from about 10 to about 24, from about 10 to about 23, from about 10
to about 22, from about 10 to about 21, from about 10 to about 20,
from about 11 to about 50, from about 12 to about 50, from about 13
to about 50, from about 14 to about 50, from about 15 to about 50,
from about 16 to about 50, from about 17 to about 50, from about 18
to about 50, from about 19 to about 50, from about 20 to about 50,
from about 10 to about 30, from about 11 to about 29, from about 12
to about 28, from about 13 to about 27, from about 14 to about 26,
from about 15 to about 25, from about 16 to about 24, from about 17
to about 23, from about 18 to about 22, from about 19 to about 21
and all ranges and sub-ranges therebetween. In one or more specific
embodiments, the copper-containing oxide may be present in the
composition in an amount of about 20 mole percent, about 25 mole
percent, about 30 mole percent or about 35 mole percent. The
copper-containing oxide may include CuO, Cu.sub.2O and/or
combinations thereof.
[0043] The copper-containing oxides in the composition form the
Cu.sup.1+ ions present in the resulting glass. Copper may be
present in the composition and/or the glasses including the
composition in various forms including Cu.sup.0, Cu.sup.1+, and
Cu.sup.2+. Copper in the Cu or Cu.sup.1+ forms provide
antimicrobial activity. However forming and maintaining these
states of antimicrobial copper are difficult and often, in known
compositions, Cu.sup.2+ ions are formed instead of the desired
Cu.sup.0 or Cu.sup.1+ ions.
[0044] In one or more aspects of the antimicrobial composite
article 100, the amount of copper-containing oxide in the glass of
the second phase particles 20 is greater than the amount of
Al.sub.2O.sub.3 in the composition. Without being bound by theory
it is believed that an about equal amount of copper-containing
oxides and Al.sub.2O.sub.3 in the composition results in the
formation of tenorite (CuO) instead of cuprite (Cu.sub.2O). The
presence of tenorite decreases the amount of Cu.sup.1+ in favor of
Cu.sup.2+ and thus leads to reduced antimicrobial activity.
Moreover, when the amount of copper-containing oxides is about
equal to the amount of Al.sub.2O.sub.3, aluminum prefers to be in a
four-fold coordination and the copper in the composition and
resulting glass remains in the Cu.sup.2+ form so that the charge
remains balanced. Where the amount of copper-containing oxide
exceeds the amount of Al.sub.2O.sub.3, then it is believed that at
least a portion of the copper is free to remain in the Cu.sup.1+
state, instead of the Cu.sup.2+ state, and thus the presence of
Cu.sup.1+ ions increases.
[0045] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 includes P.sub.2O.sub.5 in
an amount, in mole percent, in the range from about 0 to about 25,
from about 0 to about 22, from about 0 to about 20, from about 0 to
about 18, from about 0 to about 16, from about 0 to about 15, from
about 0 to about 14, from about 0 to about 13, from about 0 to
about 12, from about 0 to about 11, from about 0 to about 10, from
about 0 to about 9, from about 0 to about 8, from about 0 to about
7, from about 0 to about 6, from about 0 to about 5, from about 0
to about 4, from about 0 to about 3, from about 0 to about 2, from
about 0 to about 1, from about 0.1 to about 1, from about 0.2 to
about 1, from about 0.3 to about 1 from about 0.4 to about 1 from
about 0.5 to about 1, from about 0 to about 0.5, from about 0 to
about 0.4, from about 0 to about 0.3 from about 0 to about 0.2,
from about 0 to about 0.1 and all ranges and sub-ranges
therebetween. In some embodiments, the composition includes about
10 mole percent or about 5 mole percent P.sub.2O.sub.5 or,
alternatively, may be substantially free of P.sub.2O.sub.5.
[0046] In one or more embodiments, P.sub.2O.sub.5 forms at least
part of a less durable phase or a degradable phase in the glass
employed in the second phase particles 20 of the antimicrobial
composite article 100. The relationship between the degradable
phase(s) of the glass and antimicrobial activity is discussed in
greater detail herein. In one or more embodiments, the amount of
P.sub.2O.sub.5 may be adjusted to control crystallization of the
composition and/or glass during forming. For example, when the
amount of P.sub.2O.sub.5 is limited to about 5 mol % or less or
even 10 mol % or less, crystallization may be minimized or
controlled to be uniform. However, in some embodiments, the amount
or uniformity of crystallization of the composition and/or glass
may not be of concern and thus, the amount of P.sub.2O.sub.5
utilized in the composition may be greater than 10 mol %.
[0047] In one or more embodiments, the amount of P.sub.2O.sub.5 in
the composition may be adjusted based on the desired damage
resistance of the glass employed in the second phase particles 20
of the antimicrobial composite article 100, despite the tendency
for P.sub.2O.sub.5 to form a less durable phase or a degradable
phase in the glass. Without being bound by theory, P.sub.2O.sub.5
can decrease the melting viscosity relative to SiO.sub.2. In some
instances, P.sub.2O.sub.5 is believed to help to suppress zircon
breakdown viscosity (i.e., the viscosity at which zircon breaks
down to form ZrO.sub.2) and may be more effective in this regard
than SiO.sub.2. When glass is to be chemically strengthened via an
ion exchange process, P.sub.2O.sub.5 can improve the diffusivity
and decrease ion exchange times, when compared to other components
that are sometimes characterized as network formers (e.g.,
SiO.sub.2 and/or B.sub.2O.sub.3).
[0048] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 includes B.sub.2O.sub.3 in
an amount, in mole percent, in the range from about 0 to about 25,
from about 0 to about 22, from about 0 to about 20, from about 0 to
about 18, from about 0 to about 16, from about 0 to about 15, from
about 0 to about 14, from about 0 to about 13, from about 0 to
about 12, from about 0 to about 11, from about 0 to about 10, from
about 0 to about 9, from about 0 to about 8, from about 0 to about
7, from about 0 to about 6, from about 0 to about 5, from about 0
to about 4, from about 0 to about 3, from about 0 to about 2, from
about 0 to about 1, from about 0.1 to about 1, from about 0.2 to
about 1, from about 0.3 to about 1 from about 0.4 to about 1 from
about 0.5 to about 1, from about 0 to about 0.5, from about 0 to
about 0.4, from about 0 to about 0.3 from about 0 to about 0.2,
from about 0 to about 0.1 and all ranges and sub-ranges
therebetween. In some embodiments, the composition includes a
non-zero amount of B.sub.2O.sub.3, which may be, for example, about
10 mole percent or about 5 mole percent. The composition of some
embodiments may be substantially free of B.sub.2O.sub.3.
[0049] In one or more embodiments, B.sub.2O.sub.3 forms a less
durable phase or a degradable phase in the glass employed in the
second phase particles 20 of the antimicrobial composite article
100. The relationship between the degradable phase(s) of the glass
and antimicrobial activity is discussed in greater detail herein.
Without being bound by theory, it is believed the inclusion of
B.sub.2O.sub.3 in compositions imparts damage resistance in glasses
incorporating such compositions, despite the tendency for
B.sub.2O.sub.3 to form a less durable phase or a degradable phase
in the glass. The composition of one or more embodiments includes
one or more alkali oxides (R.sub.2O) (e.g., Li.sub.2O, Na.sub.2O,
K.sub.2O, Rb.sub.2O and/or Cs.sub.2O). In some embodiments, the
alkali oxides modify the melting temperature and/or liquidus
temperatures of such compositions. In one or more embodiments, the
amount of alkali oxides may be adjusted to provide a composition
exhibiting a low melting temperature and/or a low liquidus
temperature. Without being bound by theory, the addition of alkali
oxide(s) may increase the coefficient of thermal expansion (CTE)
and/or lower the chemical durability of the antimicrobial glasses
that include such compositions. In some cases these attributes may
be altered dramatically by the addition of alkali oxide(s).
[0050] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 may include one or more
divalent cation oxides, such as alkaline earth oxides and/or ZnO.
Such divalent cation oxides may be included to improve the melting
behavior of the compositions.
[0051] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 may include CaO in an
amount, in mole percent, in the range from about 0 to about 15,
from about 0 to about 14, from about 0 to about 13, from about 0 to
about 12, from about 0 to about 11, from about 0 to about 10, from
about 0 to about 9, from about 0 to about 8, from about 0 to about
7, from about 0 to about 6, from about 0 to about 5, from about 0
to about 4, from about 0 to about 3, from about 0 to about 2, from
about 0 to about 1, from about 0.1 to about 1, from about 0.2 to
about 1, from about 0.3 to about 1 from about 0.4 to about 1 from
about 0.5 to about 1, from about 0 to about 0.5, from about 0 to
about 0.4, from about 0 to about 0.3 from about 0 to about 0.2,
from about 0 to about 0.1 and all ranges and sub-ranges
therebetween. In some embodiments, the composition is substantially
free of CaO.
[0052] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 may include MgO in an
amount, in mole percent, in the range from about 0 to about 15,
from about 0 to about 14, from about 0 to about 13, from about 0 to
about 12, from about 0 to about 11, from about 0 to about 10, from
about 0 to about 9, from about 0 to about 8, from about 0 to about
7, from about 0 to about 6, from about 0 to about 5, from about 0
to about 4, from about 0 to about 3, from about 0 to about 2, from
about 0 to about 1, from about 0.1 to about 1, from about 0.2 to
about 1, from about 0.3 to about 1 from about 0.4 to about 1 from
about 0.5 to about 1, from about 0 to about 0.5, from about 0 to
about 0.4, from about 0 to about 0.3 from about 0 to about 0.2,
from about 0 to about 0.1 and all ranges and sub-ranges
therebetween. In some embodiments, the composition is substantially
free of MgO.
[0053] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 may include ZnO in an
amount, in mole percent, in the range from about 0 to about 5, from
about 0 to about 4, from about 0 to about 3, from about 0 to about
2, from about 0 to about 1, from about 0.1 to about 1, from about
0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1
from about 0.5 to about 1, from about 0 to about 0.5, from about 0
to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2,
from about 0 to about 0.1 and all ranges and sub-ranges
therebetween. In some embodiments, the composition is substantially
free of ZnO.
[0054] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 may include Fe.sub.2O.sub.3,
in mole percent, in the range from about 0 to about 5, from about 0
to about 4, from about 0 to about 3, from about 0 to about 2, from
about 0 to about 1, from about 0.1 to about 1, from about 0.2 to
about 1, from about 0.3 to about 1 from about 0.4 to about 1 from
about 0.5 to about 1, from about 0 to about 0.5, from about 0 to
about 0.4, from about 0 to about 0.3 from about 0 to about 0.2,
from about 0 to about 0.1 and all ranges and sub-ranges
therebetween. In some embodiments, the composition is substantially
free of Fe.sub.2O.sub.3.
[0055] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 may include one or more
colorants. Examples of such colorants include NiO, TiO.sub.2,
Fe.sub.2O.sub.3, Cr.sub.2O.sub.3, Co.sub.3O.sub.4 and other known
colorants. In some embodiments, the one or more colorants may be
present in an amount in the range up to about 10 mol %. In some
instances, the one or more colorants may be present in an amount in
the range from about 0.01 mol % to about 10 mol %, from about 1 mol
% to about 10 mol %, from about 2 mol % to about 10 mol %, from
about 5 mol % to about 10 mol %, from about 0.01 mol % to about 8
mol %, or from about 0.01 mol % to about 5 mol %. In some aspects,
the colorant employed in the second phase particles 20 is selected
to match the color of the matrix employed in the antimicrobial
composite article 100.
[0056] In one or more aspects of the antimicrobial composite
article 100, the composition of one or more embodiments of the
glass of the second phase particles 20 may include one or more
nucleating agents. Exemplary nucleating agents include TiO.sub.2,
ZrO.sub.2 and other known nucleating agents in the art. The
composition can include one or more different nucleating agents.
The nucleating agent content of the composition may be in the range
from about 0.01 mol % to about 1 mol %. In some instances, the
nucleating agent content may be in the range from about 0.01 mol %
to about 0.9 mol %, from about 0.01 mol % to about 0.8 mol %, from
about 0.01 mol % to about 0.7 mol %, from about 0.01 mol % to about
0.6 mol %, from about 0.01 mol % to about 0.5 mol %, from about
0.05 mol % to about 1 mol %, from about 0.1 mol % to about 1 mol %,
from about 0.2 mol % to about 1 mol %, from about 0.3 mol % to
about 1 mol %, or from about 0.4 mol % to about 1 mol %, and all
ranges and sub-ranges therebetween.
[0057] The glasses formed from the compositions, as employed in the
second phase particles 20 of the antimicrobial composite article
100, may include a plurality of Cu.sup.1+ ions. In some
embodiments, such Cu.sup.1+ ions form part of the glass network and
may be characterized as a glass modifier. Without being bound by
theory, where Cu.sup.1+ ions are part of the glass network, it is
believed that during typical glass formation processes, the cooling
step of the molten glass occurs too rapidly to allow
crystallization of the copper-containing oxide (e.g., CuO and/or
Cu.sub.2O). Thus the Cu.sup.1+ remains in an amorphous state and
becomes part of the glass network. In some cases, the total amount
of Cu.sup.1+ ions, whether they are in a crystalline phase or in
the glass matrix, may be even higher, such as up to 40 mol %, up to
50 mol %, or up to 60 mol %.
[0058] In one or more embodiments, the glasses formed form the
compositions disclosed herein, as employed in the second phase
particles 20 of the antimicrobial composite article 100, include
Cu.sup.1+ ions that are dispersed in the glass matrix as Cu.sup.1+
crystals. In one or more embodiments, the Cu.sup.1+ crystals may be
present in the form of cuprite. The cuprite present in the glass
may form a phase that is distinct from the glass matrix or glass
phase. In other embodiments, the cuprite may form part of or may be
associated with one or more glasses phases (e.g., the durable phase
described herein). The Cu.sup.1+ crystals may have an average major
dimension of about 5 micrometers (.mu.m) or less, 4 micrometers
(.mu.m) or less, 3 micrometers (.mu.m) or less, 2 micrometers
(.mu.m) or less, about 1.9 micrometers (.mu.m) or less, about 1.8
micrometers (.mu.m) or less, about 1.7 micrometers (.mu.m) or less,
about 1.6 micrometers (.mu.m) or less, about 1.5 micrometers
(.mu.m) or less, about 1.4 micrometers (.mu.m) or less, about 1.3
micrometers (.mu.m) or less, about 1.2 micrometers (.mu.m) or less,
about 1.1 micrometers or less, 1 micrometers or less, about 0.9
micrometers (.mu.m) or less, about 0.8 micrometers (.mu.m) or less,
about 0.7 micrometers (.mu.m) or less, about 0.6 micrometers
(.mu.m) or less, about 0.5 micrometers (.mu.m) or less, about 0.4
micrometers (.mu.m) or less, about 0.3 micrometers (.mu.m) or less,
about 0.2 micrometers (.mu.m) or less, about 0.1 micrometers
(.mu.m) or less, about 0.05 micrometers (.mu.m) or less, and all
ranges and sub-ranges therebetween. As used herein and with respect
to the phrase "average major dimension", the word "average" refers
to a mean value and the word "major dimension" is the greatest
dimension of the particle as measured by scanning electron
microscopy (SEM). In some embodiments, the cuprite phase may be
present in the glass of the second phase particles 20 of the
antimicrobial composite article 100 in an amount of at least about
10 wt %, at least about 15 wt %, at least about 20 wt %, at least
about 25 wt % and all ranges and subranges therebetween of the
antimicrobial glass. In certain implementations, the
phase-separable glasses formed from the compositions disclosed
herein, as employed in the second phase particles 20 of the
antimicrobial composite article 100, can include 10 to 50 mol %
cuprite, and all ranges and subranges therebetween, of the
phase-separable glass.
[0059] In some embodiments, the glasses as employed in the second
phase particles 20 of the antimicrobial composite article 100 may
include about 70 wt % Cu.sup.1+ or more and about 30 wt % of
Cu.sup.2+ or less. The Cu.sup.2+ ions may be present in tenorite
form and/or even in the glass (i.e., not as a crystalline
phase).
[0060] In some embodiments, the total amount of Cu by wt % in the
glasses as employed in the second phase particles 20 of the
antimicrobial composite article 100 may be in the range from about
10 to about 30, from about 15 to about 25, from about 11 to about
30, from about 12 to about 30, from about 13 to about 30, from
about 14 to about 30, from about 15 to about 30, from about 16 to
about 30, from about 17 to about 30, from about 18 to about 30,
from about 19 to about 30, from about 20 to about 30, from about 10
to about 29, from about 10 to about 28, from about 10 to about 27,
from about 10 to about 26, from about 10 to about 25, from about 10
to about 24, from about 10 to about 23, from about 10 to about 22,
from about 10 to about 21, from about 10 to about 20, from about 16
to about 24, from about 17 to about 23, from about 18 to about 22,
from about 19 to about 21 and all ranges and sub-ranges
therebetween. In one or more embodiments, the ratio of Cu.sup.1+
ions to the total amount Cu in the glass is about 0.5 or greater,
0.55 or greater, 0.6 or greater, 0.65 or greater, 0.7 or greater,
0.75 or greater, 0.8 or greater, 0.85 or greater, 0.9 or greater or
even 1 or greater, and all ranges and sub-ranges therebetween. The
amount of Cu and the ratio of Cu.sup.1+ ions to total Cu may be
determined by inductively coupled plasma (ICP) techniques known in
the art.
[0061] In some embodiments, the glass as employed in the second
phase particles 20 of the antimicrobial composite article 100 may
exhibit a greater amount of Cu.sup.1+ and/or Cu0 than Cu.sup.2+.
For example, based on the total amount of Cu.sup.1+, Cu.sup.2+ and
Cu0 in the glasses, the percentage of Cu.sup.1+ and Cu.sup.0,
combined, may be in the range from about 50% to about 99.9%, from
about 50% to about 99%, from about 50% to about 95%, from about 50%
to about 90%, from about 55% to about 99.9%, from about 60% to
about 99.9%, from about 65% to about 99.9%, from about 70% to about
99.9%, from about 75% to about 99.9%, from about 80% to about
99.9%, from about 85% to about 99.9%, from about 90% to about
99.9%, from about 95% to about 99.9%, and all ranges and sub-ranges
therebetween. The relative amounts of Cu.sup.1+, Cu.sup.2+ and
Cu.sup.0 may be determined using x-ray photoluminescence
spectroscopy (XPS) techniques known in the art.
[0062] Referring again to FIGS. 1 and 1A, the plurality of second
phase particles 20 of the antimicrobial composite article 100 can
employ a phase-separable glass. In particular, the phase-separable
glass can comprise at least a first phase and a second phase
(distinct from the second phase particles 20). In one or more
embodiments, the phase-separable glass may include two or more
phases wherein the phases differ based on the ability of the atomic
bonds in the given phase to withstand interaction with a leachate.
Specifically, the glass of one or more embodiments may include a
first phase that may be described as a degradable phase and a
second phase that may be described as a durable phase. The phrases
"first phase" and "degradable phase" may be used interchangeably.
The phrases "second phase" and "durable phase" may be used
interchangeably in the context of the phase-separable glass. As
used herein, the term "durable" refers to the tendency of the
atomic bonds of the durable phase to remain intact during and after
interaction with a leachate. As used herein, the term "degradable"
refers to the tendency of the atomic bonds of the degradable phase
to break during and after interaction with one or more leachates.
In one or more embodiments, the durable phase includes SiO.sub.2
and the degradable phase includes at least one of B.sub.2O.sub.3,
P.sub.2O.sub.5 and R.sub.2O (where R can include any one or more of
K, Na, Li, Rb, and Cs). Without being bound by theory, it is
believed that the components of the degradable phase (i.e.,
B.sub.2O.sub.3, P.sub.2O.sub.5 and/or R.sub.2O) more readily
interact with a leachate and the bonds between these components to
one another and to other components in the phase-separable glass
more readily break during and after the interaction with the
leachate. Leachates may include water, acids or other similar
materials. In one or more embodiments, the degradable phase
withstands degradation for 1 week or longer, 1 month or longer, 3
months or longer, or even 6 months or longer. In some embodiments,
longevity may be characterized as maintaining antimicrobial
efficacy over a specific period of time.
[0063] In one or more embodiments of the antimicrobial composite
article 100, the durable phase of the phase-separable glass
employed in the second phase particles is present in an amount by
weight that is greater than the amount of the degradable phase. In
some instances, the degradable phase forms islands and the durable
phase forms the sea surrounding the islands (i.e., the durable
phase). In one or more embodiments, either one or both of the
durable phase and the degradable phase may include cuprite. The
cuprite in such embodiments may be dispersed in the respective
phase or in both phases.
[0064] In some embodiments of the phase-separable glass, phase
separation occurs without any additional heat treatment of the
glass. In some embodiments, phase separation may occur during
melting and may be present when the glass composition is melted at
temperatures up to and including about 1600.degree. C. or
1650.degree. C. When the glass is cooled, the phase separation is
maintained (e.g., in a metastable state).
[0065] The phase-separable glass, as described in the foregoing,
may be provided as a sheet or may have another shape such as
particulate, fibrous, and the like. Referring to FIGS. 1 and 1A,
the phase-separable glass is in the form of second phase particles
20, generally bounded by a matrix 10 that comprises a polymeric
material. In the second phase particles 20 within the exposed
portion of exterior surface 40, the surface portion of the
particles 20 may include a plurality of copper ions wherein at
least 75% of the plurality of copper ions includes Cu.sup.1+-ions.
For example, in some instances, at least about 80%, at least about
85%, at least about 90%, at least about 95%, at least about 98%, at
least about 99% or at least about 99.9% of the plurality of copper
ions in the surface portion includes Cu.sup.1+ ions. In some
embodiments, 25% or less (e.g., 20% or less, 15% or less, 12% or
less, 10% or less or 8% or less) of the plurality of copper ions in
the surface portion include Cu.sup.2+ ions. For example, in some
instances, 20% or less, 15% or less, 10% or less, 5% or less, 2% or
less, 1% or less, 0.5% or less or 0.01% or less of the plurality of
copper ions in the surface portion include Cu.sup.2+ ions. In some
embodiments, the surface concentration of Cu.sup.1+ ions in the
antimicrobial glass is controlled. In some instances, a Cu.sup.1+
ion concentration of about 4 ppm or greater can be provided on the
surface of the antimicrobial glass.
[0066] The antimicrobial composite articles 100 according to one or
more embodiments, and particularly their exterior surfaces 30 and
40 with exposed portions, may exhibit a 2 log reduction or greater
(e.g., 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 and all ranges and
sub-ranges therebetween) in a concentration of at least one of
Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas
aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA), and
E. coli bacteria under modified United States Environmental
Protection Agency "Test Method for Efficacy of Copper Alloy
Surfaces as a Sanitizer" (2009) testing conditions, wherein the
modified conditions include substitution of the antimicrobial
composite article with the copper-containing surface prescribed in
the Method and use of copper metal article as the prescribed
control sample in the Method (collectively, the "Modified EPA
Copper Test Protocol"). As such, the United States Environmental
Protection Agency "Test Method for Efficacy of Copper Alloy
Surfaces as a Sanitizer" (2009) is hereby incorporated by reference
in its entirety within the disclosure. In some instances, the
antimicrobial composite articles exhibit at least a 4 log
reduction, a 5 log reduction or even a 6 log reduction in the
concentration of at least one of Staphylococcus aureus,
Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, MRSA, and
E. coli under the Modified EPA Copper Test Protocol.
[0067] The antimicrobial composite articles 100 according to one or
more embodiments may exhibit the log reductions described herein
for long periods of time. In other words, the articles 100 may
exhibit extended or prolonged antimicrobial efficacy. For example,
in some embodiments, the antimicrobial composite articles 100 may
exhibit the log reductions described herein under the Modified EPA
Copper Test Protocol for a week, two weeks, three weeks, up to 1
month, up to 3 months, up to 6 months or up to 12 months after the
antimicrobial composite article 100 is formed or after the
phase-separable glass is combined with a carrier (e.g., polymeric
matrix 10). These time periods may start at or after the
antimicrobial composite article 100 is formed or combined with a
carrier including but not limited to matrix 10.
[0068] According to one or more embodiments, the phase-separable
glass of the second phase particle 20 may exhibit a preservative
function, when combined with the matrix 10 described herein. In
such embodiments, the phase-separable glass may kill or eliminate,
or reduce the growth of various foulants in the matrix 10. Foulants
include fungi, bacteria, viruses and combinations thereof.
[0069] According to one or more embodiments, the antimicrobial
composite articles 100 containing the phase-separable glasses
described herein leach copper ions when exposed or in contact with
a leachate. In one or more embodiments, the glass leaches only
copper ions when exposed to leachates including water.
[0070] In one or more embodiments, the antimicrobial composite
articles 100 described herein may have a tunable antimicrobial
activity release. The antimicrobial activity of the phase-separable
glass may be caused by contact between the second phase particles
20 containing the glass and a leachate, such as water, where the
leachate causes Cu.sup.1+ ions to be released from the glass. This
action may be described as water solubility and the water
solubility can be tuned to control the release of the Cu.sup.+1
ions.
[0071] In some embodiments, where the Cu.sup.1+ ions are disposed
in the glass network and/or form atomic bonds with the atoms in the
glass network of the phase-separable glass, water or humidity
breaks those bonds and the Cu.sup.1+ ions available for release and
may be exposed on the second phase particles 20.
[0072] In one or more embodiments of the antimicrobial composite
articles 100, the phase-separable glass may be formed using formed
in low cost melting tanks that are typically used for melting glass
compositions such as soda lime silicate. Such phase-separable glass
may be formed into a sheet or directly into a particulate using
forming processes known in the art. For instance, example forming
methods include float glass processes and down-draw processes such
as fusion draw and slot draw. When the phase-separable glass is
formed into a sheet, it is subsequently ground or otherwise
processed to form the second phase particles 20 employed in the
antimicrobial composite article 100.
[0073] In some implementations, the phase-separable glass may be
incorporated into a variety of antimicrobial composite articles
(e.g., article 100) and forms, either alone or in combination with
other materials, such as electronic devices (e.g., mobile phones,
smart phones, tablets, video players, information terminal devices,
laptop computer, etc.), architectural structures (e.g., countertops
or walls), appliances (e.g., cooktops, refrigerator and dishwasher
doors, etc.), information displays (e.g., whiteboards), automotive
components (e.g., dashboard panels, windshields, window components,
etc.), counter-tops, table-tops, door knobs, rails, elevator
control panels and other article having "high touch" surfaces. When
used in such antimicrobial composite articles, the phase-separable
glass can form at least part of the housing and/or display, e.g.,
by virtue of its concentration within the article as second phase
particles 20 in the matrix 10.
[0074] After formation, the phase-separable glass may be formed
into sheets and may be shaped, polished or otherwise processed for
a desired end use. In some instances, the phase-separable glass is
ground to a powder or particulate form to serve as the second phase
particles 20 employed in the matrix 10 of the antimicrobial
composite article. The combination of the phase-separable glass and
the matrix material (e.g., a polymeric material serving as matrix
10) may be suitable for injection molding, extrusion or coatings.
Such other materials or matrix materials may include polymers,
monomers, binders, solvents, or a combination thereof as described
herein. The polymer used in the embodiments described herein can
include a thermoplastic polymer (e.g., a polyolefin), a cured
polymer (e.g., an ultraviolet- or UV-cured polymer, thermosetting
polymer, thermosetting coating, etc.), a polymer emulsion, a
solvent-based polymer, and combinations thereof. Examples of
suitable polymers include, without limitation: thermoplastics
including polysulfone (PU), polystyrene (PS), high impact PS,
polycarbonate (PC), nylon (sometimes referred to as polyamide
(PA)), poly(acrylonitrile-butadiene-styrene) (ABS), PC-ABS blends,
polybutyleneterephthlate (PBT) and PBT co-polymers,
polyethyleneterephthalate (PET) and PET co-polymers, polyolefins
(PO) including polyethylenes (PE), polypropylenes (PP),
cyclicpolyolefins (cyclic-PO), modified polyphenylene oxide (mPPO),
polyvinylchloride (PVC), acrylic polymers including polymethyl
methacrylate (PMMA), thermoplastic elastomers (TPE), thermoplastic
urethanes (TPU), polyetherimide (PEl) and blends of these polymers
with each other. Suitable injection moldable thermosetting polymers
include epoxy, acrylic, styrenic, phenolic, melamine, urethanes,
polyesters and silicone resins. In certain aspects, the matrix
material serving as matrix 10 can comprise a low (e.g., a
polyolefin) or a high (e.g., polyethyleneimine) melting point
polymeric material. According to some aspects, the matrix comprises
a low or high molecular weight polymeric material. It should also
be understood that the matrix material can comprise a bulk
polymeric material (e.g., pure polyolefin), a blend of polymeric
materials (e.g., a polyethylene/polypropylene mixture) and/or a
composite polymeric material (e.g., a polyolefin/glass composite).
Other suitable polymeric variants include linear, ladder and
branched polymers (e.g., star polymers, brush polymers and
dendrons/dentrimers). Another polymeric material variant that can
be employed for the matrix 10 includes copolymers (e.g., linear,
branched and cyclo/ring).
[0075] In other embodiments, the polymers may be dissolved in a
solvent or dispersed as a separate phase in a solvent and form a
polymer emulsion, such as a latex (which is a water emulsion of a
synthetic or natural rubber, or plastic obtained by polymerization
and used especially in coatings (as paint) and adhesives. Polymers
may include fluorinated silanes or other low friction or
anti-frictive materials. The polymers can contain impact modifiers,
flame retardants, UV inhibitors, antistatic agents, mold release
agents, fillers including glass, metal or carbon fibers or
particles (including spheres), talc, clay or mica and colorants.
Specific examples of monomers include catalyst curable monomers,
thermally-curable monomers, radiation-curable monomers and
combinations thereof.
[0076] In one or more embodiments, the phase-separable glass may be
provided in particulate form as second phase particles 20. In this
form, the phase-separable glass may have a diameter in the range
from about 0.1 micrometers (.mu.m) (.mu.m) to about 10 micrometers
(.mu.m) (.mu.m), from about 0.1 micrometers (.mu.m) (.mu.m) to
about 9 micrometers (.mu.m) (.mu.m), from about 0.1 micrometers
(.mu.m) (.mu.m) to about 8 micrometers (.mu.m) (.mu.m), from about
0.1 micrometers (.mu.m) (.mu.m) to about 7 micrometers (.mu.m)
(.mu.m), from about 0.1 micrometers (.mu.m) (.mu.m) to about 6
micrometers (.mu.m) (.mu.m), from about 0.5 micrometers (.mu.m)
(.mu.m) to about 10 micrometers (.mu.m) (.mu.m), from about 0.75
micrometers (.mu.m) (.mu.m) to about 10 micrometers (.mu.m)
(.mu.m), from about 1 micrometers (.mu.m) (.mu.m) to about 10
micrometers (.mu.m) (.mu.m), from about 2 micrometers (.mu.m)
(.mu.m) to about 10 micrometers (.mu.m) (.mu.m), from about 3
micrometers (.mu.m) (.mu.m) to about 10 micrometers (.mu.m) (.mu.m)
from about 3 micrometers (.mu.m) (.mu.m) to about 6 micrometers
(.mu.m) (.mu.m), from about 3.5 micrometers (.mu.m) (.mu.m) to
about 5.5 micrometers (.mu.m) (.mu.m), from about 4 micrometers
(.mu.m) (.mu.m), to about 5 micrometers (.mu.m) (.mu.m), and all
ranges and sub-ranges therebetween. The glass may be substantially
spherical or may have an irregular shape.
[0077] Without being bound by theory it is believed that the
combination of the phase-separable glass described herein (e.g.,
within second phase particles 20) and a matrix (e.g., matrix 1),
such as a polypropylene or polysulfone material, provides
substantially greater antimicrobial efficacy as compared to the
same matrix materials that includes only Cu.sub.2O (cuprite), even
when the same amount of copper is utilized. The presence of
Cu.sup.1+ crystals in the phase-separable glasses described herein,
even when present as cuprite, tends to remain in the Cu.sup.1+
state. Without being bound by theory, it is believed that when
Cu.sub.2O is provided alone, separate from the phase-separable
glasses described herein, the Cu ions are less stable and may
change to Cu.sup.2+ from Cu.sup.1+.
[0078] The antimicrobial performance of the antimicrobial composite
articles 100 described herein can be influenced by the presence and
thickness a thin layer of the matrix 10 coincident with or over the
second phase particles 20 on the exterior surface 40 (see FIGS. 1
and 1A). Depending on the composition of the matrix 10 and its
process history, this thin layer may exhibit hydrophobic or
substantially hydrophobic properties and may block the active
copper species (Cu.sup.1+) from exposure to air or from leaching to
the exterior surface 40. For example, a matrix 10 comprising a
polymeric material that is hydrophobic or substantially hydrophobic
(e.g., a polyolefin) can result in such a thin layer. In one or
more embodiments, the articles 100 may also use polymers as the
matrix 10 that have balanced hydrophobic-hydrophilic properties
that facilitate leaching of the active copper species. Examples of
such polymers include hygroscopic/water soluble polymers and
surfactants, amphiphilic polymers (e.g., poly(vinyl
alcohol-co-ethylene)) and/or a combination of amphiphilic polymers
and hygroscopic materials. In other implementations, the matrix 10
may comprise a polymeric material with substantially hydrophilic
properties (e.g., poly(vinyl alcohol)).
[0079] In one or more embodiments, the exposure to air and/or
leaching of the active copper species to the surface may be
facilitated by configuring the articles 100 such that its exterior
surface 40 (and, in some cases, exterior surfaces 30) with an
"exposed portion". As used herein, such an "exposed portion" is a
portion of an exterior surface of the antimicrobial composite
article 100 that has been mechanically and/or chemically treated to
expose at least some of the second phase particles 20 containing
the phase-separable glass contained in the article 100 (and
surrounded by matrix 10) to the air or to provide some portion of
the phase-separable glass at the exterior surfaces 30, 40 of the
article. Specific methods for providing an exposed portion of an
exterior surface include sanding, polishing, plasma treating (e.g.,
air, N.sub.2, O.sub.2, H.sub.2, N.sub.2 and/or Argon based plasma)
and other methods that will remove a thin layer of the matrix 10
(e.g., a polymeric material). In one or more alternative
embodiments, the exposed portion of the exterior surfaces 30, 40
includes functional groups, particularly hydroxyl and carbonyl
groups, which are introduced into or to the exposed treated
surface, to make such surface more hydrophilic. By providing an
exposed portion of an exterior surface, the active copper species
is exposed to air or more readily leaches the surface of the
article 100.
[0080] To improve processing, mechanical properties and
interactions between the matrix 10 (e.g., a polymeric material) and
the second phase particles 20 (e.g., phase-separable glass)
described herein (including any fillers and/or additives that may
be used), processing agents/aids may be included in the
antimicrobial composite articles 100 described herein. Exemplary
processing agents/aids can include solid or liquid materials. The
processing agents/aids may provide various extrusion benefits, and
may include silicone based oil, wax and free flowing fluoropolymer.
In other embodiments, the processing agents/aids may include
compatibilizers/coupling agents, e.g., organosilicon compounds such
as organo-silanes/siloxanes that are typically used in processing
of polymer composites for improving mechanical and thermal
properties. Such compatibilizers/coupling agents can be used to
surface modify the glass and can include
(3-acryloxy-propyl)trimethoxysilane;
N-(2-aminoethyl)-3-aminopropyltrimethoxysilane;
3-aminopropyltri-ethoxysilane; 3-aminopropyltrimethoxysilane;
(3-glycidoxypropyl)trimethoxysilane;
3-mercapto-propyltrimethoxysilane;
3-methacryloxypropyltrimethoxysilane; and
vinyltrimethoxysilane.
[0081] In some embodiments, the antimicrobial composite articles
100 described herein may include fillers including pigments, that
are typically metal based inorganics can also be added for color
and other purposes, e.g., aluminum pigments, copper pigments,
cobalt pigments, manganese pigments, iron pigments, titanium
pigments, tin pigments, clay earth pigments (naturally formed iron
oxides), carbon pigments, antimony pigments, barium pigments, and
zinc pigments.
[0082] After combining the phase-separable glass described herein
with a matrix 10, as described herein, the combination may be
formed into a desired antimicrobial composite article 100. Examples
of such articles 100 include housings for electronic devices (e.g.,
mobile phones, smart phones, tablets, video players, information
terminal devices, laptop computer, etc.), architectural structures
(e.g., countertops or walls), appliances (e.g., cooktops,
refrigerator and dishwasher doors, etc.), information displays
(e.g., whiteboards), and automotive components (e.g., dashboard
panels, windshields, window components, etc.).
[0083] In one or more embodiments, the articles 100 may exhibit
desired porosity and may be made into different shapes, including
complex shapes and in different forms including plastics, rubbers
and fiber/fabrics, which can have the same or different
applications. Porous articles can also be used as antimicrobial
filters. For example, the articles may be extruded into a honeycomb
structure, which not only includes channels but also porous channel
walls.
[0084] In other embodiments, the articles 100 may include a high
glass loading associated with the second phase particles 20. Such
articles may be formed from a melting process or the wet process.
In such embodiments, in addition to using the articles 100
themselves as an antimicrobial material, the matrix 10 (e.g., a
polymeric material) can be burnt out or removed to (i.e., the
article employs the matrix 10 as a fugitive material) provide a
pure copper glass antimicrobial article that is porous, with a
simple or complex shape.
[0085] Cu(I) is an excellent catalyst for organic reactions,
particularly for mild organic reactions, such as polymerization of
acrylic monomers and oleochemical applications (e.g.,
hydrogenolysis of fatty esters to fatty alcohols including both
methyl ester and wax ester processes, alkylation of alcohols with
amines and amination of fatty alcohols), just to name a few. The
antimicrobial composite articles 100 described herein may be used
for such catalyst-oriented applications, even if not employed in an
application that utilizes their inherent antimicrobial
properties.
[0086] Referring to FIG. 1B, an energy dispersive spectroscopy
(EDS) image of phase-separable glass in an exterior surface of an
antimicrobial composite article is provided according to an aspect
of the disclosure that is comparable to the antimicrobial composite
article 100 schematically depicted in FIG. 1. More specifically,
the phase-separable glass in the EDS image in FIG. 1B is exemplary
of the second phase particles 20 in an exposed portion of an
exterior surface 40 (see FIG. 1A). In FIG. 1B, the phase-separable
glass was prepared according to U.S. patent application Ser. No.
14/623,077, filed on Feb. 16, 2015, the salient portions of which
related to phase-separable glass processing are hereby incorporated
by reference within this disclosure. In FIG. 1B, the glass depicted
in the EDS image is a phase-separable phosphate glass that contains
cuprite crystals (.about.35 mol % cuprite) with a particle size of
100 to 250 nm in the discontinuous, low durability phase (i.e., the
phosphate phase) and possesses a high antimicrobial efficacy. In
addition, the phase-separable phosphate glass comprises carbon
black concentrate for color (i.e., Clariant Corporation SL94620036
carbon black). Further, the phase-separable glass depicted in FIG.
1B can be jet milled to a powder form and sieved (e.g., with a 325
mesh) to form a particulate for use as second phase particles 20 in
an antimicrobial composite article 100. The particulate can then be
compounded with a matrix polymer (e.g., serving as matrix 10) to
obtain the final antimicrobial composite article form.
[0087] In an aspect of the disclosure, the foregoing antimicrobial
composite article 100 containing the phase-separable glass depicted
in FIG. 1B can be compounded with polypropylene (serving as the
matrix) with an extrusion process. For example, a Leistritz AG
MIC18-7R GL twin-screw extruder can be employed for this process
according to the representative conditions outlined below in Table
1. The extruder can then be employed to produce the antimicrobial
composite strip 100A (see FIG. 2) without a carbon black colorant
and a set of antimicrobial composite pellets 100B (see FIG. 2) with
a carbon black colorant. Note that the pellets 100B were obtained
by a further processing of the strip obtained from the
extruder.
TABLE-US-00001 TABLE ONE Extruder speed (RPM) 700 Zone 1 (.degree.
C.) 210 Zone 2 (.degree. C.) 220 Zone 3 (.degree. C.) 225 Zone 4
(.degree. C.) 230 Zone 5 (.degree. C.) 235 Zone 6 (.degree. C.) 240
Die (.degree. C.) 240 Melt Pressure (MPa) 1.4 Air Cooling Pressure
(MPa) N/A
[0088] Referring to FIG. 3, an extruded antimicrobial composite
form (e.g., the strip and pellets of FIG. 2) can be injection
molded or otherwise processed into a sheet form as a coupon. In
particular, FIG. 3 presents photographs of the antimicrobial
composite coupons 100A' and 100B'. The coupons 100A' and 100B' were
prepared by injection molding the antimicrobial composite strip
100A and pellets 100B (see FIG. 2), respectively.
[0089] Referring again to FIG. 3, the antimicrobial composite
coupons 100A' and 100B' are 2.5 cm.times.2.5 cm square coupons
suitable for antimicrobial efficacy testing with the Modified EPA
Copper Test Protocol. Through various antimicrobial efficacy tests
conducted under the Modified EPA Copper Test Protocol of coupons
fabricated according to the foregoing antimicrobial composite
article 100 forms, it was apparent that the as-fabricated
composites can possess a thin layer of polymeric matrix material at
an exterior surface subject to such testing. Without being bound by
theory, it is believed that a thin layer of such matrix material
can prevent the copper in the phase-separable glass from being
effectively exposed to the air and bacteria to obtain high
antimicrobial efficacy. It is also believed, without being bound by
theory, that antimicrobial efficacy can depend on the degree of
hydrophobicity (or, conversely, hydrophilicity) associated with the
matrix material at an exterior surface subject to the testing. For
example, such composite articles having polymeric matrix materials
that exhibit substantial hydrophobicity are prone to a scenario in
which the bacteria (typically in an aqueous medium) does not
uniformly spread across the exterior surface under test, resulting
in lower than desired antimicrobial efficacy levels.
[0090] According to an aspect of the disclosure, exterior surfaces
of the antimicrobial composite articles (e.g., exterior surface 40
of the article 100 depicted in FIGS. 1 and 1A) can be subjected to
(a) mechanical removal of a thin layer of polymeric matrix
material; and/or (b) surface chemistry modifications to introduce
hydrophilic groups. With regard to the mechanical removal approach,
hand sanding, grit blasting, polishing and other forms of material
removal processes can be employed on such exterior surfaces to
expose a larger amount of the surface area associated with the
second phase particles containing the phase-separable glass with
the copper-containing antimicrobial agent. Suitable approaches
include hand sanding, e.g., with a 3M.TM. Contour Surface sanding
sponge, to remove about 5 to 10 mg of material from the exterior
surface of the antimicrobial composite article. The optical
micrographs in FIG. 4 with a 350 micron scale demonstrate an
exterior surface of an antimicrobial composite article with a
polypropylene matrix and a phase-separable copper-containing glass
before and after such a hand sanding procedure. Another mechanical
material removal approach is sand blasting, e.g., with standard,
known sand blasting equipment employing silica sand particulate.
Typical sand blasting conditions employ sand at 0.1 to 0.5 MPa for
10 to 60 seconds of exposure.
[0091] As for the surface modification approach, various techniques
and processes may be employed to introduce hydrophilic groups on to
the exterior surface 40 of the antimicrobial composite article 100.
In one aspect, the exterior surface 40 is subjected to a plasma
treatment with a Nordson March Plasmod system. Such a system can be
employed to plasma treat the exterior surfaces of the antimicrobial
composite articles, e.g., at 75 W for 8 min in an air or oxygen
atmosphere. As shown in the optical micrographs of FIG. 5, an
exterior surface of an antimicrobial composite article with a
polypropylene matrix and a phase-separable copper-containing glass
demonstrates a significant increase in wetting of an aqueous
bacteria solution (e.g., as consistent with bacteria-containing
media in the Modified EPA Copper Test Protocol) after such a plasma
treatment step. In particular, the image on the left side of FIG. 5
depicts an exterior surface of the composite article wetted with
the bacteria-containing solution before being subjected to the
plasma treatment. The image on the right depicts an exterior
surface of the composite article wetted with the same
bacteria-containing solution after the surface had been subjected
to a plasma treatment.
[0092] Without being bound by theory, it is believed that a
combination of the foregoing mechanical material removal and
surface chemistry modification approaches results in an exterior
surface 40 of an antimicrobial composite article with very high
antimicrobial efficacy levels, well above the levels that can be
achieved by the use of either of techniques alone. Moreover, the
sequencing of these techniques does not appear to influence the
final antimicrobial efficacy levels achieved by such antimicrobial
composite articles. Accordingly, an aspect of the disclosure
involves the combination of mechanical material removal and surface
chemistry modification to exterior surfaces of an antimicrobial
composite article, conducted in either order.
[0093] According to an aspect of the disclosure, a method 200 of
making an antimicrobial composite article 100 is provided, as shown
in FIG. 6. In particular, the method includes a step 110 for
providing a matrix (e.g., matrix 10--see FIG. 1) comprising a
polymeric material; and a step 120 for providing a plurality of
second phase particles (e.g., second phase particles 20) comprising
an antimicrobial agent. Further, the method 200 includes a step 130
for melting the matrix 10 to form a matrix melt. Next, the method
200 includes a step 140 for distributing the plurality of second
phase particles 20 in the matrix melt at a second phase volume
fraction to form a composite melt; and a step 150 for forming a
composite article 60 from the composite melt. In addition, the
method 200 includes a final step 160 for treating the composite
article 60 to form an antimicrobial composite article 100 having an
exterior surface (e.g., exterior surface 40) comprising an exposed
portion of the matrix and the plurality of second phase
particles.
[0094] Referring again to FIG. 6, the step 170 of the method 200 of
making an antimicrobial composite article 100 includes a step 170A
for abrading (e.g., material removal from an exterior surface
through mechanical means) the composite article and a step 170B for
plasma-treating the composite article 60, both steps conducted to
develop the antimicrobial composite article 100. As shown in FIG.
6, steps 170A and 170B can be performed in either order. According
to a further aspect of the method 200, step 170A for abrading the
composite article can be used alone to form the antimicrobial
composite article 100 for the specific situation in which the
matrix material (e.g., matrix 10) primarily comprises a
hydrophilic, polymeric material. As the matrix material is already
in a hydrophilic state, it stands to reason the exterior surfaces
of the composite article will also be hydrophilic in nature
obviating the need for a surface chemistry modification step such
as step 170A.
[0095] In some aspects, the treating step 170 of the method 200 of
making the antimicrobial composite article (see FIG. 6) can include
abrading (e.g., as in step 170A) the composite article 60 to form
an antimicrobial composite article 100 having an exterior surface
40 comprising an exposed portion of the matrix 10 and the plurality
of second phase particles 20. The abrading can be conducted with
hand sanding, grit blasting or other similar grinding and/or
polishing techniques. In other aspects of the method, the treating
step 170 can include abrading and plasma-treating (e.g., as in step
170B) the composite article 60 to form an antimicrobial composite
article 100 having an exterior surface 40 comprising an exposed
portion of the matrix 10 and the plurality of second phase
particles 20. In these implementations, the abrading can be
performed before the plasma-treating or vice versa. Further, the
plasma-treating can conducted with any of a variety of known
processes that produce or otherwise create functional groups in the
exposed portion of the matrix on the exterior surface of the
article.
[0096] According to some aspects of the method 200, the melting and
distributing steps 130 and 140, respectively, can include or
otherwise employ an extrusion process. In addition, step 140 for
distributing the second phase particles 20 in the matrix can be
conducted with a melt process (e.g., compounding/extrusion and
injection molding). Step 140 can also be conducted with a solution
process (e.g., adding the second phase particles 20 into a coating
with the matrix 10 material), a bulk polymerization process and/or
with a solution polymerization process (e.g., a suspension process
or emulsion process for the second phase particles 20). Further,
the step 150 for forming a composite article can include or
otherwise employ an injection molding process. As such, the forming
step 150 can be employed to fashion the composite article in a
final product form or a near net shape form.
[0097] In one aspect, the method 200 of making an antimicrobial
composite article 100 can include the following steps: providing a
matrix comprising a hydrophobic polymeric material (e.g., step
110); providing a plurality of second phase particles comprising a
copper-containing antimicrobial agent (e.g., step 120); melting the
matrix to form a matrix melt (e.g., step 130); extruding the
plurality of second phase particles in the matrix melt at a second
phase volume fraction to form a composite melt (e.g., step 140);
injection molding a composite article (e.g., composite article 60)
from the composite melt (e.g., step 150); and treating the
composite article to form an antimicrobial composite article having
an exterior surface comprising an exposed portion of the matrix and
the plurality of second phase particles (e.g., step 170). Further,
the exposed portion of the plurality of second phase particles is
distributed within the exposed portion of the matrix at a second
phase area fraction within 25% of the second phase volume
fraction.
[0098] Referring to FIG. 7A, a bar chart depicts the antimicrobial
efficacy (as tested with the Modified EPA Copper Test Protocol) of
antimicrobial composite articles having a polypropylene matrix and
a plurality of second phase particles comprising a phase-separable
glass with a copper-containing antimicrobial agent, and subjected
to various surface treatment steps. In FIG. 7A, the sample group
designated "C" is a control sample of pure copper material. Sample
groups "B1" through "B5" are indicative of antimicrobial composite
articles subjected to various surface treatment steps--i.e., no
treatment, plasma treatment in oxygen, plasma treatment in air,
sand blasting, and hand sanding, respectively. As demonstrated by
FIG. 7A, the various treatment steps conducted alone on the
antimicrobial composite articles provide little benefit in terms of
antimicrobial efficacy as all such samples B1-B5 demonstrated a log
kill of less 1 compared to the copper control sample C at a log
kill of 6.
[0099] FIG. 7B is a bar chart depicting the antimicrobial efficacy
(as tested with the Modified EPA Copper Test Protocol) of
antimicrobial composite articles having a polypropylene matrix and
a plurality of second phase particles comprising a phase-separable
glass with a copper-containing antimicrobial agent, and subjected
to various surface treatment steps. In FIG. 7B, the sample group
designated "C" is a control sample of pure copper material. Sample
groups "A1" through "A3" are indicative of antimicrobial composite
articles subjected to various surface treatment steps--i.e., plasma
treatment in oxygen and sand blasting, plasma treatment in air and
sand blasting, and hand sanding and plasma treatment in air,
respectively. As demonstrated by FIG. 7B, the various treatment
steps conducted in combination on the antimicrobial composite
articles provide a significant benefit in terms of antimicrobial
efficacy as all such samples A1, A2 and A3 demonstrated a log kill
of 2 or more.
[0100] FIGS. 8A & 8B are bar charts depicting the antimicrobial
efficacy (as tested with the Modified EPA Copper Test Protocol) of
antimicrobial composite articles having a polysulfone matrix and a
plurality of second phase particles comprising a phase-separable
glass with a copper-containing antimicrobial agent, and subjected
to various surface treatment steps. In both FIGS. 8A & 8B, the
sample group designated "C" is a control sample of pure copper
material. In FIG. 8A, the sample group designated "A5" is
indicative of an antimicrobial composite article subjected to
plasma treatment and sanding process steps. In FIG. 8B, the sample
group designated "B6" is indicative of an antimicrobial composite
article subjected to no surface treatments and the sample group
designated "A4" is indicative of an antimicrobial composite article
subjected to a hand sanding step followed by a plasma treatment
step in air. As demonstrated by FIGS. 8A & 8B, antimicrobial
composite articles having a polysulfone matrix and a plurality of
second phase particles comprising a phase-separable glass with a
copper-containing antimicrobial agent can exhibit antimicrobial
efficacy levels (i.e., log kill reductions of 3 or more) comparable
or even exceeding similar such antimicrobial composite articles
employing a polypropylene matrix (see, e.g., FIGS. 7A &
7B).
[0101] Referring to FIG. 9, a bar chart depicts the antimicrobial
efficacy (as tested with the Modified EPA Copper Test Protocol) of
antimicrobial composite articles having a polypropylene matrix and
a plurality of second phase particles comprising a phase-separable
glass with a copper-containing antimicrobial agent, as subjected to
various hospital grade cleaners. In FIG. 9, the sample group
designated "C" is a control sample of pure copper material. Sample
groups "A6" through "A9" are indicative of antimicrobial composite
articles subjected to a mechanical surface removal step (e.g.,
sanding) and a surface chemistry modification step (e.g., plasma
treatment in air), followed by no exposure to a hospital grade
cleaner (A6) or exposure to various hospital grade cleaners--i.e.,
10% bleach (A7), Virex Tb (A8), and Vesphene Ilse (A9). As
demonstrated by FIG. 9, the exposure to the hospital cleaners cause
no demonstrable reduction in the antimicrobial efficacy of these
antimicrobial composite articles.
[0102] FIGS. 10A & 10B are bar charts depicting the
antimicrobial efficacy (as tested with the Modified EPA Copper Test
Protocol) of antimicrobial composite articles having a
polypropylene matrix and a plurality of second phase particles
comprising a phase-separable glass with a copper-containing
antimicrobial agent, and subjected to various environmental
conditions. In both FIGS. 10A & 10B, the sample group
designated "C" is a control sample of pure copper material. In FIG.
10A, sample groups "A10" through "A13" are indicative of
antimicrobial composite articles subjected to a mechanical surface
removal step (e.g., sanding) and a surface chemistry modification
step (e.g., plasma treatment in air), followed by no exposure to an
environmental condition (A10) or exposure to various environmental
conditions--i.e., 38.degree. C./98% relative humidity for 24 hours
(A11), 85.degree. C./85% relative humidity for 24 hours (A12), and
85.degree. C./85% relative humidity for 7 days (A13). Similarly, in
FIG. 10B, sample groups "A14" through "A19" are indicative of
antimicrobial composite articles subjected to a mechanical surface
removal step (e.g., sanding) and a surface chemistry modification
step (e.g., plasma treatment in air), followed by no exposure to an
environmental condition (A14) or exposure to various environmental
conditions--i.e., 38.degree. C./98% relative humidity for 24 hours
(A15), 4 days (A16), 7 days (A17), 10 days (A18), and 14 days
(A19). As demonstrated by FIGS. 10A & 10B, the addition of the
exposure of the antimicrobial composite articles to various
environmental conditions involving increased temperature and
humidity causes no demonstrable reduction in the antimicrobial
efficacy of these antimicrobial composite articles.
[0103] Referring to FIG. 11, a bar chart depicts the antimicrobial
efficacy (as tested with the Modified EPA Copper Test Protocol) of
antimicrobial composite articles having a polypropylene matrix and
a plurality of second phase particles comprising a phase-separable
glass with a copper-containing antimicrobial agent, with and
without a subsequent fluorosilane layer over the exterior surfaces
of the article. In FIG. 11, the sample group designated "C" is a
control sample of pure copper material. Sample groups "A21" and
"A22" are indicative of antimicrobial composite article subjected
to a mechanical surface removal step (e.g., sanding) and a surface
chemistry modification step (e.g., plasma treatment in air),
followed by no additional coating (A21) or an additional
fluorosilane coating (A22), e.g., as configured for fingerprint,
smudge resistance, scratch resistance or the like. As demonstrated
by FIG. 11, the addition of the fluorosilane coating causes no
demonstrable reduction in the antimicrobial efficacy of these
antimicrobial composite articles.
[0104] Aspect (1) of this disclosure pertains to an antimicrobial
composite article, comprising: a matrix comprising a polymeric
material; and a plurality of second phase particles comprising a
phase-separable glass with a copper-containing antimicrobial agent,
wherein the plurality of particles is distributed within the matrix
at a second phase volume fraction, and further wherein the
composite article defines an exterior surface comprising an exposed
portion of the matrix and the plurality of the second phase
particles.
[0105] Aspect (2) of this disclosure pertains to the article of
Aspect (1), wherein the exposed portion of the plurality of second
phase particles is distributed within the exposed portion of the
matrix at a second phase area fraction within 25% of the second
phase volume fraction.
[0106] Aspect (3) of this disclosure pertains to the article of
Aspect (1) or Aspect (2), wherein the matrix comprises a polymeric
material characterized by substantial hydrophobicity, and further
wherein the exposed portion of the matrix is characterized by
substantial hydrophilicity.
[0107] Aspect (4) of this disclosure pertains to the article of any
one of Aspect (1) through Aspect (3), wherein the polymeric
material is selected from the group consisting of a polypropylene,
a polyolefin and a polysulfone.
[0108] Aspect (5) of this disclosure pertains to the article of
Aspect (1) through Aspect (4), wherein the phase-separable glass
comprises at least one of B.sub.2O.sub.3, P.sub.2O.sub.5 and
R.sub.2O, and the antimicrobial agent is cuprite comprising a
plurality of Cu.sup.1+ ions.
[0109] Aspect (6) of this disclosure pertains to the article of
Aspect (1) through Aspect (5), wherein the exterior surface of the
article exhibits at least a log 2 reduction in a concentration of
at least one of Staphylococcus aureus, Enterobacter aerogenes, and
Pseudomonas aeruginosa bacteria under a Modified EPA Copper Test
Protocol.
[0110] Aspect (7) of this disclosure pertains to the article of
Aspect (1) through Aspect (8), wherein the exterior surface of the
article exhibits at least a log 3 reduction in a concentration of
at least one of Staphylococcus aureus, Enterobacter aerogenes, and
Pseudomonas aeruginosa bacteria under a Modified EPA Copper Test
Protocol.
[0111] Aspect (8) of this disclosure pertains to the article of
Aspect (5), wherein the plurality of second phase particles has a
size distribution defined by a 325 standard US mesh size.
[0112] Aspect (9) of this disclosure pertains to the article of
Aspect (1) through Aspect (8), wherein the phase-separable glass
comprises between about 10 and 50 mol % cuprite.
[0113] Aspect (10) of this disclosure pertains to the article of
Aspect (1) through Aspect (9), wherein the matrix comprises a
polymeric material characterized by substantial hydrophilicity.
[0114] Aspect (11) of this disclosure pertains to the article of
Aspect (3), wherein the exposed portion of the matrix comprises
functional groups derived from a plasma treatment of the
matrix.
[0115] Aspect (12) of this disclosure pertains to the article of
Aspect (1) through Aspect (11), wherein the exterior surface of the
composite article is configured as a high touch surface of an
element selected from the group consisting of a cover screen for a
display device, a housing for a display device, a counter-top, a
table-top, a door knob, a rail, and an elevator control panel.
[0116] Aspect (13) of this disclosure pertains to a method of
making an antimicrobial composite article, comprising the steps:
providing a matrix comprising a polymeric material; providing a
plurality of second phase particles comprising an antimicrobial
agent; melting the matrix to form a matrix melt; distributing the
plurality of second phase particles in the matrix melt at a second
phase volume fraction to form a composite melt; forming a composite
article from the composite melt; and treating the composite article
to form an antimicrobial composite article having an exterior
surface comprising an exposed portion of the matrix and the
plurality of second phase particles.
[0117] Aspect (14) of this disclosure pertains to the method of
Aspect (13), wherein the matrix comprises a polymeric material
characterized by substantial hydrophilicity.
[0118] Aspect (15) of this disclosure pertains to the method of
Aspect (13) or Aspect (14), wherein the treating step comprises
abrading the composite article to form an antimicrobial composite
article having an exterior surface comprising an exposed portion of
the matrix and the plurality of second phase particles.
[0119] Aspect (16) of this disclosure pertains to the method of
Aspect (13) through Aspect (15), wherein the matrix comprises a
polymeric material characterized by substantial hydrophobicity, and
further wherein the exposed portion of the matrix is characterized
by substantial hydrophilicity.
[0120] Aspect (17) of this disclosure pertains to the method of
Aspect (16), wherein the treating step comprises abrading and a
plasma-treating the composite article to form an antimicrobial
composite article having an exterior surface comprising an exposed
portion of the matrix and the plurality of second phase
particles.
[0121] Aspect (18) of this disclosure pertains to the method of
Aspect (17), wherein the abrading is performed before the
plasma-treating during the treating step.
[0122] Aspect (19) of this disclosure pertains to the method of
Aspect (17), wherein the plasma-treating is performed before the
abrading during the treating step.
[0123] Aspect (20) of this disclosure pertains to the method of any
one of Aspect (13) through Aspect (19), wherein the polymeric
material is selected from the group consisting of a polypropylene,
a polyolefin and a polysulfone.
[0124] Aspect (21) of this disclosure pertains to the method of any
one of Aspect (13) through Aspect (20), wherein the second phase
particles further comprise an SiO.sub.2-containing glass and at
least one of B.sub.2O.sub.3, P.sub.2O.sub.5 and R.sub.2O, and
further wherein the antimicrobial agent is cuprite comprising a
plurality of Cu.sup.1+ ions.
[0125] Aspect (22) of this disclosure pertains to the method of any
one of Aspect (13) through Aspect (21), wherein the melting and
distributing steps comprise an extrusion process and the forming a
composite article step comprises an injection molding process.
[0126] Aspect (23) of this disclosure pertains to the method of any
one of Aspect (13) through Aspect (22), wherein the exterior
surface of the antimicrobial composite article exhibits at least a
log 2 reduction in a concentration of at least one of
Staphylococcus aureus, Enterobacter aerogenes, and Pseudomonas
aeruginosa bacteria under a Modified EPA Copper Test Protocol.
[0127] Aspect (24) of this disclosure pertains to the method of any
one of Aspect (13) through Aspect (23), wherein the exterior
surface of the antimicrobial composite article exhibits at least a
log 3 reduction in a concentration of at least one of
Staphylococcus aureus, Enterobacter aerogenes, and Pseudomonas
aeruginosa bacteria under a Modified EPA Copper Test Protocol.
[0128] Aspect (25) of this disclosure pertains to a method of
making an antimicrobial composite article, comprising the steps:
providing a matrix comprising a hydrophobic polymeric material;
providing a plurality of second phase particles comprising an
copper-containing antimicrobial agent; melting the matrix to form a
matrix melt; extruding the plurality of second phase particles in
the matrix melt at a second phase volume fraction to form a
composite melt; injection molding a composite article from the
composite melt; and treating the composite article to form an
antimicrobial composite article having an exterior surface
comprising an exposed portion of the matrix and the plurality of
second phase particles, wherein the exposed portion of the
plurality of second phase particles is distributed within the
exposed portion of the matrix at a second phase area fraction
within 25% of the second phase volume fraction.
[0129] It will be apparent to those skilled in the art that various
modifications and variations can be made without departing from the
spirit or scope of the invention.
* * * * *